Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Research and Innovation Action · Running

NEXGEN-PD Next Generation Vaccine Platform Leveraging Skin Immunity to Provide Disease-Modifying Treatment of Parkinson’s Disease

Coordinator
Tridem Bioscience GmbH & Co Kg, Austria
Runs
1 April 2023 to 31 March 2027
Status
Running
EU funding
€6.1m
Total cost
€6.1m
Partners
12 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101080267

What the project is doing

In the project's own words, from its summary on CORDIS.

Parkinson’s Disease (PD) is a major neurodegenerative disorder with no established treatment modalities capable of modifying disease pathology, and no means of early diagnosis. Vaccines targeting aSyn aggregates are a promising route to disease-modifying therapy for PD, but the current generation of PD vaccines utilise conventional formulations, which are limited in their immunogenicity and require substantial quantities of adjuvant to achieve efficacy.

NEXGEN’s proprietary WISIT vaccine platform is the first of the novel class of gluconeoconjugate vaccines (GNCVs), which are administered intradermally and specifically formulated to leverage skin dendritic cells (DCs) to generate substantially stronger and more specific immune responses than conventional vaccines. These stronger immune responses allow substantial reduction in adjuvants, while simultaneously increasing therapy efficacy.

NEXGEN will identify and characterise candidate WISIT constructs targeting aSyn (PD-WISITs) and develop a novel extracellular vesicle (EV)-based biomarker assay that enables early diagnosis of PD using liquid biopsies, suitable for point of care use. Safety and efficacy of PD-WISITs will be demonstrated preclinically, before being translated to first-in-human Phase I/Ib clinical trials, along with the novel EV-based biomarker assay.

The results of NEXGEN will be the extraordinary accomplishments of cheap and effective disease-modifying treatment of early PD and a novel biomarker assay to diagnose and guide prodromal/early PD treatment. Further still, GNCV technology will be clinically demonstrated, which has the potential to be transformative to the treatment of a wide range of additional diseases, resulting in far-reaching impacts to the health of millions.

Topics

Who is involved

OrganisationCityCountryRole
Tridem Bioscience GmbH & Co KgWienAustriaCoordinator
Austrian Red Cross Research GmbHWienAustriaParticipant
Gouya Insights GmbH & Co KgWienAustriaParticipant
Paracelsus Medizinische Privatuniversitat Salzburg - PrivatstiftungSalzburgAustriaParticipant
Prosenex Ambulatorium BetriebsgmbhWienAustriaParticipant
Granzer Heinz-UlrichMunchenGermanyParticipant
Philipps Universitaet MarburgMarburgGermanyParticipant
Motac FranceFloiracFranceParticipant
Aurigon Labs Zartkoruen Mukodo ReszvenytarsasagDunakesziHungaryParticipant
Kineto Lab. Kutatas-Fejlesztesi Es Tanacsado KftBudapestHungaryParticipant
Institute for Medical Technology Assessment BVRotterdamNetherlandsParticipant
Modus Research and Innovation LimitedDundeeUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI